Brokers Offer Predictions for OS Therapies Q1 Earnings

OS Therapies Inc (NYSE:OSTX) – Equities research analysts at Brookline Capital Management issued their Q1 2025 EPS estimates for OS Therapies in a research note issued to investors on Wednesday, April 2nd. Brookline Capital Management analyst K. Raja anticipates that the company will post earnings per share of ($0.11) for the quarter. The consensus estimate for OS Therapies’ current full-year earnings is ($0.64) per share. Brookline Capital Management also issued estimates for OS Therapies’ Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.10) EPS and Q4 2025 earnings at ($0.10) EPS.

A number of other brokerages have also recently commented on OSTX. Lake Street Capital began coverage on shares of OS Therapies in a report on Wednesday. They set a “buy” rating and a $19.00 target price for the company. D. Boral Capital reaffirmed a “buy” rating and issued a $20.00 target price on shares of OS Therapies in a report on Monday, March 31st. Finally, Maxim Group lifted their target price on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, January 16th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $18.00.

OS Therapies Stock Down 9.1 %

NYSE OSTX opened at $1.40 on Friday. The company has a 50-day moving average price of $1.77 and a 200-day moving average price of $2.68. OS Therapies has a 52 week low of $1.33 and a 52 week high of $7.00.

Institutional Trading of OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC acquired a new stake in shares of OS Therapies Inc (NYSE:OSTX) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 10,045 shares of the company’s stock, valued at approximately $28,000.

Insider Transactions at OS Therapies

In other news, major shareholder Shalom Auerbach sold 16,720 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $6.74, for a total value of $112,692.80. Following the transaction, the insider now directly owns 2,531,211 shares in the company, valued at $17,060,362.14. The trade was a 0.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 13.80% of the company’s stock.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.